BTK and mantle cell lymphoma: As a first-generation BTK inhibitor, ibrutinib was rapidly approved by the US Food and Drug Administration (FDA) for the treatment of CLL/SLL and MCL (mantle cell lymphoma) in 2014 and 2013, respectively.